Log in or Sign up for Free to view tailored content for your specialty!
Cutaneous Oncology News
Educational status, ethnicity play role in melanoma awareness
Socioeconomic disparities may lead to a lower awareness of melanoma and its dangers, especially among those who are Hispanic, according to a cross-sectional study presented at the American Academy of Dermatology virtual meeting.
Fewer nivolumab doses with ipilimumab appear effective in unresectable melanoma
The first two doses of nivolumab with ipilimumab appeared to drive efficacy and toxicity of the combination among certain patients with melanoma, according to phase 2 study results presented during the ASCO20 Virtual Scientific Program.
Log in or Sign up for Free to view tailored content for your specialty!
ALA-PDT safe, effective in actinic keratoses
Aminolevulinic acid 20% combined with photodynamic therapy was more effective in clearing actinic keratoses on the upper extremities, meaning the arms from elbows to base of the fingers, compared to vehicle, according to a poster presented at the American Academy of Dermatology virtual meeting.
Multiple aggregated yellow-white globules may aid BCC diagnosis
Multiple aggregated yellow-white globules were observed in more than one-fifth of basal cell carcinoma cases in a case-control study.
Voriconazole may be associated with squamous cell carcinoma risk in lung transplants
Lung transplant recipients who were treated with voriconazole to prevent aspergillosis were significantly more likely than those who did not receive voriconazole to develop squamous cell carcinoma, according to a study.
Ipilimumab-pembrolizumab combination appears promising for advanced melanoma
Pembrolizumab plus low-dose ipilimumab demonstrated antitumor activity among patients with advanced melanoma who failed prior treatment, according to phase 2 study results presented during the ASCO20 Virtual Scientific Program.
Melanoma Research Foundation presents Humanitarian Award
Melanoma Research Foundation will present its Humanitarian Award to Andrew E. Aplin, PhD.
No significant link found between biologics, melanoma development in inflammatory diseases
Patients treated with biologic therapy for inflammatory diseases may not have a higher risk for developing melanoma, a systematic review and meta-analysis found.
Adjuvant pembrolizumab confers durable RFS benefit in resected stage III melanoma
Adjuvant pembrolizumab taken for up to 1 year conferred a durable, clinically meaningful RFS benefit for patients with resected high-risk stage III melanoma, according to study results presented during the ASCO20 Virtual Scientific Program.
Adjuvant dabrafenib-trametinib provides ‘real chance to cure’ BRAF-mutant melanoma
Adjuvant dabrafenib and trametinib provided long-term benefit for patients with resected stage III BRAF V600-mutant melanoma, according to an analysis of the COMBI-AD trial presented during the ASCO20 Virtual Scientific Program.
-
Headline News
‘Truly alarming’: Life expectancy gap in the US now up to 20 years
November 22, 20243 min read -
Headline News
Autoantibodies present in long COVID, but not a ‘smoking gun’ for new autoimmune disease
November 25, 20242 min read -
Headline News
Cardiovascular disease deaths rising among younger adults living in rural areas
November 15, 20243 min read
-
Headline News
‘Truly alarming’: Life expectancy gap in the US now up to 20 years
November 22, 20243 min read -
Headline News
Autoantibodies present in long COVID, but not a ‘smoking gun’ for new autoimmune disease
November 25, 20242 min read -
Headline News
Cardiovascular disease deaths rising among younger adults living in rural areas
November 15, 20243 min read